TCG Advisors LP Sells 2,112 Shares of Amgen, Inc. (NASDAQ:AMGN)
TCG Advisors LP reduced its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 26.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 5,731 shares of the medical research company’s stock after selling 2,112 shares during the quarter. TCG Advisors LP’s holdings in Amgen were worth $1,162,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. Sugarloaf Wealth Management LLC purchased a new position in Amgen during the 4th quarter worth approximately $57,000. CFM Wealth Partners LLC acquired a new position in Amgen during the 4th quarter worth $926,000. Putnam FL Investment Management Co. lifted its position in Amgen by 17.7% during the 4th quarter. Putnam FL Investment Management Co. now owns 55,760 shares of the medical research company’s stock worth $13,442,000 after acquiring an additional 8,401 shares during the last quarter. Smead Capital Management Inc. lifted its position in Amgen by 0.9% during the 4th quarter. Smead Capital Management Inc. now owns 634,139 shares of the medical research company’s stock worth $152,872,000 after acquiring an additional 5,753 shares during the last quarter. Finally, Concorde Asset Management LLC bought a new position in shares of Amgen during the 4th quarter worth about $207,000. Institutional investors and hedge funds own 75.75% of the company’s stock.
AMGN has been the topic of several research analyst reports. Credit Suisse Group reaffirmed a “buy” rating and set a $252.00 price objective on shares of Amgen in a research note on Sunday, February 2nd. Cfra increased their price objective on shares of Amgen from $223.00 to $259.00 and gave the company a “buy” rating in a report on Friday, May 1st. SunTrust Banks increased their target price on shares of Amgen from $254.00 to $265.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. JPMorgan Chase & Co. reissued a “hold” rating on shares of Amgen in a research report on Sunday, February 2nd. Finally, Argus reaffirmed a “buy” rating and issued a $265.00 target price on shares of Amgen in a research report on Thursday, February 6th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seventeen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $244.65.
Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $4.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.70 by $0.47. Amgen had a net margin of 32.03% and a return on equity of 90.75%. The firm had revenue of $6.16 billion during the quarter, compared to analyst estimates of $6.01 billion. During the same quarter in the prior year, the business posted $3.56 EPS. The business’s revenue was up 10.9% compared to the same quarter last year. On average, equities analysts expect that Amgen, Inc. will post 15.58 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, June 8th. Stockholders of record on Monday, May 18th will be paid a $1.60 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.40 annualized dividend and a dividend yield of 2.82%. Amgen’s payout ratio is 43.18%.
In related news, Director Ronald D. Sugar sold 1,000 shares of the stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $229.27, for a total transaction of $229,270.00. Following the completion of the transaction, the director now owns 16,482 shares in the company, valued at $3,778,828.14. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director R Sanders Williams sold 425 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $237.31, for a total transaction of $100,856.75. Following the transaction, the director now owns 5,834 shares of the company’s stock, valued at approximately $1,384,466.54. The disclosure for this sale can be found here. In the last quarter, insiders sold 2,425 shares of company stock valued at $563,477. Company insiders own 0.36% of the company’s stock.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Recommended Story: Diluted Earnings Per Share
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.